OncoMatch/Clinical Trials/NCT06205836
Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer
Is NCT06205836 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cemiplimab and Fianlimab for colorectal cancer.
Treatment: Cemiplimab · Fianlimab — The purpose of this study is to evaluate the safety and clinical activity of cemiplimab and the combination of cemiplimab/fianlimab in microsatellite unstable localized or locally advanced colorectal cancer diagnosed in patients age 70 or greater or in patients age 18 or greater considered poor candidates for surgery or unwilling to undergo surgery.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic therapy
Must not have received any prior systemic treatment
Cannot have received: radiation therapy
Must not have received any prior...radiation
Cannot have received: anti-PD-1 therapy
History of prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4, or anti-Lag-3 antibodies for any reason in the 5 years proceeding their colorectal cancer diagnosis
Lab requirements
Blood counts
adequate organ and marrow function defined by study-specified laboratory tests and procedures
Kidney function
adequate organ and marrow function defined by study-specified laboratory tests and procedures
Liver function
adequate organ and marrow function defined by study-specified laboratory tests and procedures
Cardiac function
lvef assessment with documented lvef ≥ 45% by either tte or muga (tte preferred) within 6 months from first study drug administration
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Johns Hopkins SKCCC · Baltimore, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify